FTAI Reports Second Quarter 2017 Results, Dividend of $0.33 per Common Share
Aug 03, 2017 20:15 pm UTC| Business
NEW YORK, Aug. 03, 2017 -- Fortress Transportation and Infrastructure Investors LLC (NYSE:FTAI) (the “Company”) today reported financial results for the three months ended June 30, 2017. The Company’s consolidated...
ARCA biopharma Announces Second Quarter 2017 Financial Results and Provides Business Update
Aug 03, 2017 20:15 pm UTC| Business
WESTMINSTER, Colo., Aug. 03, 2017 -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today...
Ducommun Reports Results for the Second Quarter Ended July 1, 2017
Aug 03, 2017 20:15 pm UTC| Business
SANTA ANA, Calif., Aug. 03, 2017 -- Ducommun Incorporated (NYSE:DCO) (“Ducommun” or the “Company”) today reported results for its second quarter ended July 1, 2017. Second Quarter 2017 Highlights Revenue of $140.9...
The Cooper Companies Announces Release Date for Third Quarter 2017
Aug 03, 2017 20:15 pm UTC| Business
PLEASANTON, Calif., Aug. 03, 2017 -- The Cooper Companies, Inc. (NYSE:COO) today announced it will release third quarter 2017 financial results on Thursday, August 31, 2017, at 4:15 PM ET. Following the release, the...
Valero Signs Long-Term Agreements to Import Refined Products into Central Mexico
Aug 03, 2017 20:14 pm UTC| Business
SAN ANTONIO, Aug. 03, 2017 -- Valero Marketing and Supply de México, S.A. de C.V., an indirect wholly-owned subsidiary of Valero Energy Corporation (NYSE:VLO) (“Valero”), announced today that it has signed long-term...
Aug 03, 2017 20:13 pm UTC| Business
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2017 -- Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) today announced that on August 3, 2017 it resubmitted its Biologics License Application (BLA) to the Center for Biologics...
Otonomy Reports Second Quarter 2017 Financial Results and Provides Corporate Update
Aug 03, 2017 20:12 pm UTC| Business
SAN DIEGO, Aug. 03, 2017 -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear, today reported...